Exciva is a clinical stage biopharmaceutical company focused on delivering an innovative treatment to address symptoms of Alzheimer’s patients.
Location: Germany
Total raised: $70.1M
Investors 2
| Date | Name | Website |
| 15.11.2021 | LBBW Ventu... | lbbwvc.de |
| - | Andera Par... | anderapart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.01.2026 | Series B | $59.64M | Andera Par... |
| 27.10.2021 | Series A | $10.46M | - |
Mentions in press and media 11
| Date | Title | Description |
| 22.01.2026 | Exciva Secures €51 Million Series B: Alzheimer's Agitation Therapy Advances to Phase 2 | Exciva closed a €51 million Series B funding round. This financing fuels Deraphan, its Alzheimer's agitation therapy, into crucial Phase 2 trials. EQT Life Sciences and Gimv spearheaded the investment. The global study addresses a pressing ... |
| 20.01.2026 | Exciva raises €51M in Series B Funding | Exciva, a Heidelberg, Germany-based biopharmaceutical company developing new therapeutic compounds for the treatment of neuropsychiatric conditions, raised €51M in Series B funding. The round was led by Gimv and EQT Life Sciences. Additiona... |
| 20.01.2026 | German BioTech Exciva lands €51 million to advance Alzheimer’s drug testing in patients | Heidelberg-based Exciva, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59 million) Series B round. Gimv and EQT Life Scien... |
| 20.01.2026 | Exciva: €51 Million Series B Closed To Advance Alzheimer’s Agitation Therapy Into Phase 2 | EQT Life Sciences announced it co-led a €51 million Series B financing in Exciva, a clinical-stage biopharmaceutical company developing treatments for behavioral symptoms associated with Alzheimer’s disease, with proceeds earmarked to move ... |
| 20.01.2026 | Andera Partners’ Portfolio Company Exciva Secures €51 Million Series B to Advance Clinical Program for Alzheimer’s-Related Agitation. | Andera Partners, a leading European private equity player, today announced that it participated in the €51 million ($59 million) Series B financing round of its portfolio company Exciva GmbH, a biopharmaceutical company developing novel the... |
| 20.01.2026 | EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer’s therapy into clinical Phase 2 | EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer’s therapy into clinical Phase 2 Tue, Jan 20, 2026 07:30 CET Report this content Series B financing will support Exciva’s Phase 2 clinical trial of its lea... |
| 03.05.2022 | Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs | Andera Partners, a leading European private equity player, through its biotech and medtech practice Andera Life Sciences, announced today that it is leading a €60 million (USD $63 million) Series B financing round for Tubulis with participa... |
| 27.10.2021 | German biotech startup Exciva secures €9M to address ‘Agitation/Aggression’ in Alzheimer’s disease | Germany-based Exciva, a clinical-stage biotech company developing a novel therapeutic compound for treating agitation and aggression in Alzheimer’s disease, announced that it has raised €9M in its Series A round of funding.Investors in this... |
| 27.10.2021 | Biotech startup Exciva scores €9M Series A | Germany-based Exciva has raised €9 million in a round led by Andera Partners. The startup is developing a treatment for behavioral and psychological symptoms in Alzheimer's disease patients. The capital will be used to fund a Phase I clinic... |
| 26.10.2021 | Exciva Raises €9M in Series A Funding | Exciva GmbH, a Heidelberg, Germany-based clinical biotech company developing a novel therapeutic compound for treating agitation/aggression in Alzheimer’s disease, closed a €9m ($10M) Series A financing. The round was led by Andera Partners... |
Show more